Patents Examined by Shengjun Wang
  • Patent number: 11510902
    Abstract: A method for preventing or treating a non-alcoholic fatty liver disease in a subject who is at risk of suffering from the non-alcoholic fatty liver disease or suffers from the non-alcoholic fatty liver disease, by administering to the subject a composition comprising a therapeutically effective amount of Antrodins.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 29, 2022
    Inventors: Chia-Chin Sheu, Tse-Kai Fu
  • Patent number: 11504380
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 22, 2022
    Assignee: INVENTIVA
    Inventors: Guillaume Wettstein, Pierre Broqua, Jean-Louis Junien
  • Patent number: 11497746
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 15, 2022
    Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
  • Patent number: 11497942
    Abstract: The present invention is a cosmetic or dermatological preparation comprising 0.01% by weight to 5% by weight of at least one red light-filtering dye and 0.0001% by weight to 10% by weight of at least one anti-inflammatory active ingredient. The preparation can be used for the prophylaxis and treatment of sun-irritated skin and to aid the body's own repair mechanisms.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: November 15, 2022
    Assignee: BEIERSDORF AG
    Inventors: Rainer Kröpke, Ludger Kolbe, Anette Bürger, Claudia Mundt
  • Patent number: 11491128
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: November 8, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Marco Fazzari, Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 11478435
    Abstract: The present disclosure relates to an artificial saliva gel and uses thereof to treat or ameliorate dry mouth (xerostomia). The gel can be of a high viscosity that is maintained at body temperature or when exposed to bodily fluids (for instance, saliva). In some embodiments, the gel can act as a lubricant. Although water-based, the gel can be hydrophobic and not readily dissolvable in bodily fluids. In some embodiments, the gel can be sterile, safe for long-term repeated ingestion, and include a preservative. In some embodiments, the gel can comprise a dental agent for inhibiting growth of dental microorganisms. In order to achieve sterility while maintaining a desired viscosity range, the gel can include a viscosity stabilising agent such as a viscosity protection agent for protection from radiation induced breakdown. The gel can also include a coloring and/or a flavoring agent.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: October 25, 2022
    Assignee: Smilesonica Inc.
    Inventors: Cristian Scurtescu, Gleam Gill
  • Patent number: 11464765
    Abstract: Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 11, 2022
    Inventors: Haitao Yang, Zhenming Jin, Xiuna Yang, Yao Zhao, Zihe Rao
  • Patent number: 11458136
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 4, 2022
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard E. Gendelman, Benson Edagwa
  • Patent number: 11458203
    Abstract: The present disclosure relates to pharmaceutical compositions comprising caffeic acid chelates, kits, and methods for using such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 4, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Thomas Cahill, Jeffrey Langland, Bertram Jacobs, Carl Wagner, Guillermo Ruiz
  • Patent number: 11446303
    Abstract: Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: September 20, 2022
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Heshan Peiris, Philip Liaw, Brian D. Frenzel
  • Patent number: 11447501
    Abstract: A biphenyl-containing diarylpyrimido compound of formula (I), which is prepared by reacting a 4-chloropyrimidine derivative with a biphenyl derivative in a solvent in the presence of a base. A pharmaceutically-acceptable salt of the compound (I) and a pharmaceutical composition containing the compound (I) or a pharmaceutically-acceptable salt thereof are also provided.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: September 20, 2022
    Assignee: Fudan Univeristy
    Inventors: Fener Chen, Yali Sang, Chunlin Zhuang
  • Patent number: 11446236
    Abstract: A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes nitrofurantoin combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: September 20, 2022
    Inventor: Jay Richard Ray, II
  • Patent number: 11447512
    Abstract: An antiviral nucleoside reverse transcriptase inhibitor compound as shown in formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form or an isotopic derivative of the compound. A preparation method therefor, a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating and/or preventing viral infectious diseases, such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: September 20, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao
  • Patent number: 11446353
    Abstract: The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may be Valley Fever.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: September 20, 2022
    Assignees: The Translational Genomics Research Institute, Arizona Board of Regents on behalf of Northern Arizona University
    Inventors: David Engelthaler, Elizabeth Driebe, Hongwei “Holly” Yin, Michael Valentine, Donald Chow, Jolene Bowers, Paul Keim, Bridget Barker
  • Patent number: 11439638
    Abstract: A method for treating an early-stage microbial infection comprising determining whether a subject exposed to a coronavirus, such as SARS-CoV-2, or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and, if the subject is infected with the coronavirus, administering an antimicrobial agent is provided herein.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: September 13, 2022
    Assignee: Feynman Labs, LLC
    Inventors: Carl Johan Freer, Richard Kaszynski, Alessandro Gadotti
  • Patent number: 11434249
    Abstract: Described herein are compounds, including pharmaceutically acceptable salts and solvates thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: September 6, 2022
    Inventor: Samuel David Brown
  • Patent number: 11426362
    Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: August 30, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Patent number: 11426375
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 30, 2022
    Assignee: Novartis AG
    Inventors: Yongshuai Chai, Sven Erik Godtfredsen, Mark Kagan, Yugang Liu, Mahavir Prashad, Zhaoyin Wang, Saijie Zhu
  • Patent number: 11413254
    Abstract: The present invention provides a use of (2R,4R)-1,2,4-trihydroxy heptadec-16-yne or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or an enantiomer thereof in the preparation of a pharmaceutical composition for preventing or treating liver injury.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 16, 2022
    Assignee: NORBEL BABY CO., LTD.
    Inventors: Jin-Ching Lee, Hsun-Shuo Chang, Ih-Sheng Chen, Chin-Kai Tseng, Chun-Kuang Lin
  • Patent number: 11400098
    Abstract: The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 2, 2022
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Teruaki Nakatsuji